Literature DB >> 12527799

Opioids bind to the amino acids 84 to 118 of UDP-glucuronosyltransferase UGT2B7.

Birgit L Coffman1, William R Kearney, Shawn Goldsmith, Boyd M Knosp, Thomas R Tephly.   

Abstract

The UDP-glucuronosyltransferase UGT2B7 is an important human UGT isoform that catalyzes the conjugation of many endogenous and exogenous compounds, among them opioids, resulting in the formation of D-glucuronides. The binding site of the aglycone is located in the N-terminal half of the protein. Using NMR analysis, we demonstrate that the opioid binding site in UGT2B7 is within the 84 to 118 N-terminal amino acids. Three maltose binding protein-UGT2B7 fusion proteins, 2B7F3 and 2B7F4 incorporating the amino acids 24 to 118 and 24 to 96 of UGT2B7, respectively, and 2B7F5 incorporating amino acids 84 to 118 of UGT2B7 were expressed in Escherichia coli and purified by affinity chromatography. NMR analysis showed that morphine was bound to the fusion protein 2B7F3 with a K(D) value similar to the K(D) values obtained for the previously produced fusion proteins, which included amino acids 24 to 180. Morphine did not bind to 2B7F4, but it did bind to 2B7F5. Both NMR 1-D spectra and NOESY experiments indicated that the 2B7F5 protein was mediating magnetization transfer within the morphine. These results allowed us to predict and model a binding site within the amino acids 96 to 101 of UGT2B7. A mutant fusion protein 2B7F3 with the substitution D99A was produced, and the NMR spectroscopy analysis of the protein supported the model. A marked reduction of morphine binding was observed when the charged aspartate was substituted with alanine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527799     DOI: 10.1124/mol.63.2.283

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  Stable isotope-labelled morphine to study in vivo central and peripheral morphine glucuronidation and brain transport in tolerant mice.

Authors:  Ivan Weinsanto; Alexis Laux-Biehlmann; Jinane Mouheiche; Tando Maduna; François Delalande; Virginie Chavant; Florian Gabel; Pascal Darbon; Alexandre Charlet; Pierrick Poisbeau; Marc Lamshöft; Alain Van Dorsselaer; Sarah Cianferani; Marie-Odile Parat; Yannick Goumon
Journal:  Br J Pharmacol       Date:  2018-08-31       Impact factor: 8.739

Review 2.  The crystal structure of human UDP-glucuronosyltransferase 2B7 C-terminal end is the first mammalian UGT target to be revealed: the significance for human UGTs from both the 1A and 2B families.

Authors:  Anna Radominska-Pandya; Stacie M Bratton; Matthew R Redinbo; Michael J Miley
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

3.  Molecular cloning of the baboon UDP-glucuronosyltransferase 2B gene family and their activity in conjugating morphine.

Authors:  Kirsten Abildskov; Piper Weldy; Marianne Garland
Journal:  Drug Metab Dispos       Date:  2010-01-13       Impact factor: 3.922

4.  The first aspartic acid of the DQxD motif for human UDP-glucuronosyltransferase 1A10 interacts with UDP-glucuronic acid during catalysis.

Authors:  Yan Xiong; Anne-Sisko Patana; Michael J Miley; Agnieszka K Zielinska; Stacie M Bratton; Grover P Miller; Adrian Goldman; Moshe Finel; Matt R Redinbo; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2007-11-29       Impact factor: 3.922

5.  Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis.

Authors:  Janet K Coller; Julia Beardsley; James Bignold; Yibai Li; Florence Merg; Thomas Sullivan; Timothy C Cox; Andrew A Somogyi
Journal:  Pharmgenomics Pers Med       Date:  2009-03-20

6.  Human variability in isoform-specific UDP-glucuronosyltransferases: markers of acute and chronic exposure, polymorphisms and uncertainty factors.

Authors:  E E J Kasteel; K Darney; N I Kramer; J L C M Dorne; L S Lautz
Journal:  Arch Toxicol       Date:  2020-05-15       Impact factor: 5.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.